Craig-Hallum initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart
- Eledon Pharmaceuticals: Promising Advances in Organ Transplant Rejection Prevention with Tegoprubart
- Eledon Pharmaceuticals’ Tegoprubart: Promising Clinical Potential in Kidney Transplantation and Strategic Targeting Advantages
- Sernova enters collaborative research agreement with Eledon Pharmaceuticals
- Eledon Pharmaceuticals assumed with a Buy at H.C. Wainwright